215917-98-9

Usage

Uses

Used in Organic Synthesis:
(S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate is utilized as a key intermediate in organic synthesis for the construction of various complex organic molecules. Its unique structural features and reactivity facilitate the synthesis of a wide range of compounds, contributing to the advancement of chemical research and development.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate serves as a valuable precursor in the development of novel drug molecules. Its potential biological activity and the ability to be modified and incorporated into diverse molecular frameworks make it an attractive candidate for the creation of new therapeutic agents with improved efficacy and selectivity.
Used in Chiral Chemistry:
The presence of two stereocenters in (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate makes it an important player in chiral chemistry. It can be employed as a chiral building block or as a resolving agent to produce enantiomerically pure compounds, which are crucial in the development of enantioselective reactions and the synthesis of chiral pharmaceuticals.
Used in Material Science:
(S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate may also find applications in material science, where its unique properties can be harnessed to develop new materials with specific characteristics. For instance, its use in the synthesis of chiral polymers or as a component in self-assembling systems could lead to materials with novel properties and applications.

Upstream product

• 106825-79-0 (S)-morpholine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67-56-1 methanol 
• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 1235387-14-0 C₁₃H₁₇NO₃ 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 1447972-26-0 methyl (3S)-morpholine-3-carboxylate hydrochloride 

Relevant academic research and scientific papers

Preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid

The invention provides a preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid, which comprises the following steps: (1) carrying out an amino protection reaction on chiralserinamide and an amino protective agent to obtain a com

NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS

The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C1-C3alkyl optionally substituted by halogen; R2 is C1-C6alkyl optionally substituted one or more times by C1-C6alkyl, C2-C6alkenyl, hydroxyl, N,N-di-C1-C6alkyl amino, N-mono-C1-C6alkyl amino, O-Rg, Rg, phenyl, or by C1-C6alkoxy wherein said alkoxy again may optionally be substituted by C1-C6alkoxy, N,N-di-C1-C6alkyl amino, Rg or phenyl; C3-C6cycloalkyl optionally substituted by C1-C6alkyl, N,N-di-C1-C6alkyl amino or C1-C6alkoxy-C1-C6alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C1-C6alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C1-C6alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C1-C6alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS

The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from(a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16,(e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and(g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, ?and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5—(d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.